Search Results - "Chirivella, I."

Impact of the COVID-19 Pandemic on a Cancer Fast-Track Programme by Martínez, M. T., Moragon, S., Ortega-Morillo, B., Montón-Bueno, J., Simon, S., Roselló, S., Insa, A., Viala, A., Navarro, J., Sanmartín, A., Fluixá, C., Julve, A., Soriano, D., Buch, E., Peña, A., Franco, J., Martínez-Jabaloyas, J., Marco, J., Forner, M. J., Cano, A., Silvestre, A., Teruel, A, Bermejo, B., Cervantes, A., Chirivella Gonzalez, I.

“…Introduction The COVID-19 pandemic has disrupted many aspects of clinical practice in oncology, particularly regarding early cancer diagnosis, sparking public…”
Get full text

SEOM clinical guidelines in Hereditary Breast and ovarian cancer by Llort, G., Chirivella, I., Morales, R., Serrano, R., Sanchez, A. Beatriz, Teulé, A., Lastra, E., Brunet, J., Balmaña, J., Graña, B.

“…Approximately, 7 % of all breast cancers (BC) and 11–15 % of ovarian cancers (OC) are associated with inherited predisposition, mainly related to germline…”
Get full text

SEOM clinical guideline for treatment of kidney cancer (2019) by Lázaro, M., Valderrama, B. P., Suárez, C., de-Velasco, G., Beato, C., Chirivella, I., González-del-Alba, A., Laínez, N., Méndez-Vidal, M. J., Arranz, J. A.

“…In this article, we review de state of the art on the management of renal cell carcinoma (RCC) and provide recommendations on diagnosis and treatment. Recent…”
Get full text

Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial by Martín-Martorell, P, Roselló, S, Rodríguez-Braun, E, Chirivella, I, Bosch, A, Cervantes, A

“…This is a phase II institutional exploratory trial of biweekly irinotecan and cetuximab administration regimen in metastatic colorectal cancer patients…”
Get full text

SEOM clinical guideline for treatment of kidney cancer (2017) by Gallardo, E., Méndez-Vidal, M. J., Pérez-Gracia, J. L., Sepúlveda-Sánchez, J. M., Campayo, M., Chirivella-González, I., García-del-Muro, X., González-del-Alba, A., Grande, E., Suárez, C.

“…The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer…”
Get full text

Oncological emergencies by Cervantes, A., Chirivella, I.

Get full text

2638 Effectiveness of 2nd-line and subsequent therapies after pazopanib (Paz) in patients (pt) with metastatic renal cell carcinoma (mRCC): Final results of the SPAZO study (SOGUG) by Arija, J.A. Arranz, Pérez-Valderrama, B, González-Larriba, J.L, Rodríguez Sánchez, A, Chirivella, I, Pinto, A, Marrero, R.D. García, Rubio, G, García, J.M. Jurado, Borrega, P, Quintela, M. Lázaro, Castellano, D.E, Rodríguez, C. Suárez, García, J.A. Meana, Lambea-Sorrosal, J.J, Gajate, P, Fita, M.J. Juan, Puertas, J.L, Domínguez, R. García, Guzmán, J.C. Villa

Get full text

Clinical guideline seom: hereditary colorectal cancer by Guillén-Ponce, C., Serrano, R., Sánchez-Heras, A. B., Teulé, A., Chirivella, I., Martín, T., Martínez, E., Morales, R., Robles, L.

“…Genetic mutations have been identified as the cause of inherited cancer risk in some colon cancer; these mutations are estimated to account for only 5–6 % of…”
Get full text

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study by Alcaraz, A, González-López, R, Morote, J, de la Piedra, C, Meseguer, C, Esteban, E, Climent, M, González-Gragera, B, Álvarez-Ossorio, J-L, Chirivella, I, Mellado, B, Lara, P-C, Vázquez, F, Contreras, J-A, Carles, J, Murias, A, Calderero, V, Comet-Batlle, J, González-del Alba, A, León-Mateos, L, Mañas, A, Segarra, J, Lassa, A, González-Enguita, C, Méndez, M-J, Samper, P, Unda, M, Mahillo-Fernández, I, Bellmunt, J

“…Background: Levels of bone turnover markers (BTM) might be correlated with outcome in terms of skeletal-related events (SRE), disease progression, and death in…”
Get full text

Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC) by Andrés, R., Pajares, I., Balmaña, J., Llort, G., Ramón y Cajal, T., Chirivella, I., Aguirre, E., Robles, L., Lastra, E., Pérez-Segura, P., Bosch, N., Yagüe, C., Lerma, E., Godino, J., Miramar, M. D., Moros, M., Astier, P., Saez, B., Vidal, M. J., Arcusa, A., Ramón y Cajal, S., Calvo, M. T., Tres, A.

“…Background BRCA1-associated breast cancers have been associated to a triple-negative phenotype. The prevalence of BRCA1 germline mutations in young onset TNBC…”
Get full text

Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer by Pérez-Fidalgo, J. A., Bermejo, B., Chirivella, I., Martínez, M. T., González, I., Cejalvo, J. M., Catoira, I., Martínez, P., Contel, E., Lluch, A.

“…Purpose To evaluate the impact on survival of the relative dose intensity (RDI) achieved in patients with early breast cancer receiving anthracycline plus…”
Get full text

Molecular biology of gastric cancer by Cervantes, A, Rodríguez Braun, E, Pérez Fidalgo, A, Chirivella González, I

“…Despite its decreasing incidence overall, gastric cancer is still a challenging disease. Therapy is based mainly upon surgical resection when the tumour…”
Get full text

Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment by Martínez, M. T., González, I., Tarazona, N., Roselló, S., Saiz, R., Sanmartín, A., Martínez-Agulló, Á., Caballero, A., Mas, P., Franco, J., Martínez-Jabaloyas, J., García-Callejo, J., Martín, V., Navarro, J., Teruel, A., Lluch, A., Chirivella, I.

“…Purpose This study aims to asses a cancer fast-track programme (CFP) to shorten the time since a patient with suspicion of cancer is referred by the primary…”
Get full text

A multimodality approach to localized rectal cancer by Cervantes, A., Chirivella, I., Rodriguez-Braun, E., Campos, S., Navarro, S., García Granero, E.

Get full text

Clinical guideline seom: hereditary colorectal cancer by Guillén-Ponce, C., Serrano, R., Sánchez-Heras, A. B., Teulé, A., Chirivella, I., Martín, T., Martínez, E., Morales, R., Robles, L.

Get full text

(005) A Systematic Review of Preventative BRCA Surgeries and Sexual Function Outcomes by Belda, R, Morgan, O, Chirivella, I, Schnur, J, Cano, A

“…Abstract Introduction BRCA 1 and 2 genes increase a patient’s risk for developing cancer of breast and ovarian origin. There are two methods of preventative…”
Get full text

Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: Identification of three novel pathogenic mutations by Martínez-Ferrandis, J.I., Vega, A., Chirivella, I., Marín-García, P., Insa, A., Lluch, A., Carracedo, A., Chaves, F.J., García-Conde, J., Cervantes, A., Armengod, M.-E.

“…In Spain, the contribution of BRCA mutations to the population incidence of early‐onset breast cancer was unknown. We carried out a mutational analysis of the…”
Get full text

Parotid gland metastasis of a breast cancer by Perez-Fidalgo, J A, Chirivella, I, Laforga, J, Colio, J M, Blanes, M D, Baydal, R, Roselló, S, De-la-Morena, E, Lluch, A

“…Parotid gland metastases from malignant tumors are extremely rare. A 61-year-old woman was diagnosed with an early breast cancer with no expression of…”
Get full text

Correction to: SEOM clinical guideline for treatment of kidney cancer (2017) by Gallardo, E., Méndez-Vidal, M. J., Pérez-Gracia, J. L., Sepúlveda-Sánchez, J. M., Campayo, M., Chirivella-González, I., García-del-Muro, X., González-del-Alba, A., Grande, E., Suárez, C.

“…The conflict of interest declaration was published incorrectly in the original version…”
Get full text

Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation by Martínez, M.T., Montón-Bueno, J., Simon, S., Ortega, B., Moragon, S., Roselló, S., Insa, A., Navarro, J., Sanmartín, A., Julve, A., Buch, E., Peña, A., Franco, J., Martínez-Jabaloyas, J., Marco, J., Forner, M.J., Cano, A., Silvestre, A., Teruel, A., Lluch, A., Cervantes, A., Chirivella Gonzalez, I.

“…Cancer is the second leading cause of mortality worldwide. Integrating different levels of care by implementing screening programmes, extending diagnostic…”
Get full text